CVSI seems to have bottomed out and offers a good risk/reward ratio.
CV Science is a Cannabidiol (CBD) producer and its product is the #1 selling natural hemp extract in the USA.
Keep in mind that this is an OTC stock.
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharmaceutical segments. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol products through the PlusCBD brand. The Specialty Pharmaceutical segment...
CVSI had a brutal last year, but is fighting for fresh support and just broke the longstanding bear trendline suggesting that a turnaround could be in the cards.
-----------------------------
CV Sciences Inc (OTCMKTS:CVSI)
CV Sciences bills itself as a company that operates two distinct business segments: a drug development division focused on developing and...
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharmaceutical segments. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol products through the PlusCBD brand. The Specialty Pharmaceutical segment...
Entry level $2.50 with stop loss $2.15 = Profit target $4.00
Average Analysts recommendation = buy with a $6.33 price target.
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharmaceutical segments. The Consumer Products segment includes...
$CVSI has been beaten up along with the rest of the cannabis sector.
Recent price action indicates that the low might be in as the critical $1.55 support level held.
Next major resistance level is $3. Those that want to go Long can buy with a stop below $1.55 and add to the position on a break above $3.
$CVSI is well-known because of its top-selling PlusCBD...
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharmaceutical segments. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol products through the PlusCBD brand. The Specialty Pharmaceutical segment...
OTC:CVSI is still a STRONG BUY.
This company produces CBD and is a beneficiary of the newly passed FARM bill.
Currently CVSI, is in Primary Wave 3 and it has extended. Primary Wave 3 has traveled over 700% of Wave 1 thus far. We have had a brief correction here but CVSI looks to be starting a new wave sequence now.
Immediate Target = $8.35
If $8.35...
bullish engulfing candlestick. I am long and will be keeping an eye on this one. Financials are great. Best of Breed in the CBD oil space and frankly, I am surprised this didn't break out yet. I think it is coming. It gained over a 1000% in 2018. Stay tuned.
